LF
ITCI

Lee Financial’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Lee Financial’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-260
Closed -$18.6K – 855
2023
Q4 		$18.6K Hold
260
– – ﹤0.01% 330
2023
Q3 		$13.5K Hold
260
– – ﹤0.01% 361
2023
Q2 		$16.5K Hold
260
– – ﹤0.01% 333
2023
Q1 		$14.1K Buy
260
+40
+18% +$1.93K ﹤0.01% 364
2022
Q4 		$11.6K Hold
220
– – ﹤0.01% 434
2022
Q3 		$10K Buy
+220
New +$11.5K ﹤0.01% 445
2019
Q4 		– Sell
-500
Closed -$4K – 527
2019
Q3 		$4K Buy
+500
New +$4.79K ﹤0.01% 444
2018
Q4 		– Sell
-200
Closed -$4K – 485
2018
Q3 		$4K Sell
200
-150
-43% -$3.14K ﹤0.01% 430
2018
Q2 		$6K Buy
350
+267
+322% +$5.42K ﹤0.01% 604
2018
Q1 		$2K Buy
+83
New +$1.62K ﹤0.01% 711

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Lee Financial's ITCI Position: Q1 2024 in Review

Lee Financial sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2024, closing a stake of 260 shares — an estimated $18.6K sold.

Lee Financial first reported a position in ITCI in Q1 2018 and held it in 10 quarters. The position peaked at $18.6K in Q4 2023. 345 funds tracked by Wall St. Rank hold ITCI as of Q1 2024.

  • Lee Financial reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2024 after selling out during the quarter.
  • Lee Financial sold 260 Intra-Cellular Therapies Inc. shares in Q1 2024, an estimated $18.6K.
  • Lee Financial first reported a position in Intra-Cellular Therapies Inc. in Q1 2018 and held it in 10 quarters.
  • Lee Financial's Intra-Cellular Therapies Inc. position peaked at $18.6K in Q4 2023.
  • 345 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2024.

Based on Lee Financial's 13F filing for Q1 2024, filed 15 May 2024.